INTRODUCTION
============

Gene-directed enzyme-prodrug therapy (GDEPT) or suicide gene therapy is comprised of three components; the prodrug to be activated, the enzyme (usually nonhuman) used for activation, and the delivery system for the corresponding gene \[[@B1]\]. Most attention to date has been directed towards development of the vector systems, on which there is a large literature. This review focuses on the small molecule prodrugs used in such therapies. Prodrugs can be considered as comprised of two major domains; a "trigger" unit that is the substrate for the activating enzyme, and an "effector" unit that is activated or released by this metabolic process, sometimes joined by a definable linker \[[@B2]\] ([Figure 1](#F1){ref-type="fig"}).

As well as being an efficient and selective substrate for the activating enzyme, the prodrug itself needs to be a systemic agent, metabolically stable and able to diffuse efficiently by paracellular and/or transcellular routes to the areas in the tumor where the activating enzyme is being generated. The effector that is activated or released from the prodrug must be an effective cytotoxin (preferably able to kill cells at all stages of the cell cycle), but must also have good bystander effects (an ability to diffuse to and kill neighbouring tumor cells). Most delivery systems still have very low efficiencies of gene transduction, and the bystander effect of the effector species is important in compensating for this \[[@B3]\]. The physicochemical properties that govern these desirable pharmacokinetic characteristics of both prodrugs and effectors are beginning to be understood, and include molecular size, overall lipophilicity, charge, rate of metabolism, and the propensity to form reversible or irreversible complexes with cellular macromolecules.

![Trigger-linker-effector concept for prodrug design.](20909.fig.001){#F1}

![Activation of ganciclovir and analogues by HSV-Tk.](20909.fig.002){#F2}
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\(a\) Activation of cyclophosphamide and ifosfamide of CYP. (b) Activation of acetaminophen by CYP.
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\(a\) Activation of mustards by CPG2. (b) Activation of anthracycline glutamates by CPG2. (c) Activation of methotrexate-α-peptides by CPGA.
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\(a\) Activation of irinotecan by CE. (b) Activation of doxorubicin acetal by CE.
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\(a\) Activation of CB1954 by NTR. (b) Activation of SN23862 by NTR.
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![Activation of 4-nitrobenzyl carbamates by NTR.](20909.fig.009){#F9}

![Activation of IAA and FIAA by HRP.](20909.fig.010){#F10}

![Activation of 6-thioxanthine by GPT.](20909.fig.011){#F11}

![Activation of anthracycline by glycosidases.](20909.fig.012){#F12}

![Activation of 5′-DFUR by TP.](20909.fig.013){#F13}

![Activation of selenomethionine by MET.](20909.fig.014){#F14}

The next section provides a brief overview of prodrugs that have been explored for use in GDEPT, and their corresponding effectors. These are grouped according to the activating enzyme, and do not provide extensive details of relative levels of use but focus on the chemistry of the prodrugs. [Table 1](#T1){ref-type="table"} provides a broad categorization of the DNA binding of the prodrugs (and their activated forms) discussed here, based on the knowledge of their structure. Most have little or no ability to bind reversibly to DNA, some are likely to have significant binding constants, and many (especially the activated forms) can covalently react with DNA. Since both reversible and irreversible binding lower the free drug concentration that drives diffusion, the level of DNA binding can significantly influence the bystander effect. The lipophilicity of both the prodrug and the activated drug also has an important influence on bystander abilities \[[@B4]\]. [Table 1](#T1){ref-type="table"} contains log P values (n-octanol/water partition coefficents) for the compounds, calculated using the Advanced Chemistry Development (ACD) 5.0 Software package. These calculated values are approximations, and can differ substantially from measured values in some series, but in the absence of measured values for most of the compounds serve to at least rank the compounds overall. For those possessing ionizable centres, log D~7~ values are used; these take into account the log P values of the neutral and ionized forms and the relative proportions of each at pH 7.

###### 

Estimated physicochemical properties governing the bystander effects of GDEPT prodrugs and their principal effectors.

  ------------------- ------------ -------- ----------------- -------------- ---------
    Prodrug           Effector                                               
                                                                             
  No                  log P^a^     DNA^b^   No                log P^a^       DNA^b^
                                                                             
                                                                             
                                                                             
  **1a** (GCV)        −2.07        low      **1b**            −6.70^c^       low
                                                                             
  **2a** (E-GCV)       7.0         low      **1b**            −6.70^c^       low
                                                                             
  **3a** (PCV)        −2.03        low      **3b**            −6.71^c^       low
                                                                             
  **4a** (ACV)        −1.76        low      **4b**            −6.34^c^       low
                                                                             
  **5a** (VCV)        −0.78        low      **4b**            −6.34^c^       low
                                                                             
  **6a** (BVDU)       −0.43        low      **6b**            −5.25^c^       low
                                                                             
  **7a** (AZT)        −0.58        low      **7b**            −5.46          low
                                                                             
  **8a** (MCT)        −1.77        low      **8b**            −6.49^c^       low
                                                                             
  **9a** (5-FC)       −1.79^c^     low      **9b** (5-FU)     −2.17^c^       low
                                                                             
  **10a** (MEP)       −0.35        low      **10b**              0.09^c^     low
                                                                             
  **11a** (FAMP)      −2.32        low      **11b**           −1.26^c^       low
                                                                             
  **12a** (CPA)          0.23      low      **12b**           −3.95^c^       bond^d^
                                                                             
  **13a** (IFO)          0.50      low      **12b**           −3.95^c^       bond^d^
                                                                             
  **14a**                0.34      low      **14b** (NABQI)      0.38        bond^d^
                                                                             
  **15a** (4-IM)         0.70      low      unknown               ---        bond^d^
                                                                             
  **16a** (CMDA)      −4.67^c^     low      **16b**              0.05        bond^d^
                                                                             
  **17a**             −3.09^c^     low      **17b**              1.66        bond^d^
                                                                             
  **18a**             −1.62^c^     low      **18b**              3.73        bond^d^
                                                                             
  **19a**             ∼ 3.0        high     **19b** (DOX)        0.34^c^     high
                                                                             
  **20a** (MTX-Phe)      2.74      low      **20b** (MTX)     −0.28          low
                                                                             
  **21a** (IRT)          1.54^c^   low      **21b** (SN-38)      2.02        low
                                                                             
  **22a**                2.04^c^   high     **22b**              1.51^c^     bond^d^
                                                                             
  **23a** (CB1954)       1.28      low      **23b**           −0.34          bond^d^
                                                                             
  **24a** (SN23862)      2.06      low      **24b**              2.50        bond^d^
                                                                             
  **29a**                4.40      medium   **29b**              4.13        medium
                                                                             
  **32a**                4.55      medium   **32b**              1.87        bond^d^
                                                                             
  **35a** (IAA)       −0.81^c^     low      **35b**              1.35        high
                                                                             
  **36a** (FIAA)      −1.09^c^     low      **36b**              1.80        bond^d^
                                                                             
  **37a** (6-TX)      −0.41^c^     low      **37b**           −5.52^c^       low
                                                                             
  **38a** (HM1826)       1.53      high     **19b**              0.36^c^     high
                                                                             
  **39a**                0.78      high     **22b**              1.51        bond^d^
                                                                             
  **40a**                0.78      high     **22b**              1.51        bond^d^
                                                                             
  **41a** (5′-DFUR)   −0.82        low      **9b**            −2.17^c^       low
                                                                             
  **42a** (SeMET)     −3.15^c^     low      **42b**              0.72^d,e^   low
  ------------------- ------------ -------- ----------------- -------------- ---------

a Calculated using Advanced Chemistry Development (ACD) Software 5.0 package. b Estimate (based on structure only) of the level of reversible binding to DNA. c log D at pH 7 for compounds with ionizable groups. d Covalent alkylation of DNA. e Calculated for S analogue.

PRODRUGS FOR THYMIDINE KINASE (TK)
==================================

Introduction
------------

The most prominent GDEPT therapy has been the use of the herpes simplex type-1 thymidine kinase enzyme (HSV-Tk) in conjunction with a variety of guanosine-based prodrugs, compounds originally developed as antiviral (anti-herpes) agents \[[@B5], [@B6]\]. The enzyme converts these prodrugs very efficiently (much more efficiently than the corresponding endogenous kinases) to the monophosphates, which are then converted by cellular enzymes to the toxic triphosphates ([Figure 2](#F2){ref-type="fig"}). These cause cell death by inhibition of incorporation of dGTP into DNA, and also by prevention of chain elongation \[[@B7]\]. Fusion proteins of HSV-Tk with green fluorescent protein showed that enzyme expression was predominantly in the nucleus of both transduced human and rodent glioma cells \[[@B8]\]. A study using positron-emission tomography (PET) showed that the extent of gene expression correlated with therapeutic response in glioma \[[@B9]\].

Ganciclovir (GCV; 1a)
---------------------

This is the most widely used prodrug for HSV-Tk, and is well known in its own right as an antiviral agent \[[@B6]\]. It is a very hydrophilic compound (calculated log P − 2.07; see [Table 1](#T1){ref-type="table"}). The HSV-Tk enzyme converts this to the monophosphate (**1b**) which can then be converted by cellular enzymes to the toxic triphosphate ([Figure 2](#F2){ref-type="fig"}). The high cytotoxicity shown by GCV in HSV-Tk transduced cells is suggested to be due to its enhanced ability, compared to related prodrugs, to incorporate into DNA without inhibiting progression through the S-phase \[[@B10]\]. In CHO cells, GCV is a potent inducer of chromosome breaks and sister chromatid exchange at concentrations well below those required for its gene therapy activity \[[@B11]\].

The monophosphate effector **1b** is more polar than GCV even as the neutral form (log P = −2.6), but is also partially ionized to an anionic species, giving a calculated partition coefficient at pH 7 (log D~7~) of −6.7 ([Table 1](#T1){ref-type="table"}). Although this species has very limited ability to cross cell membranes by passive diffusion, HSV-Tk/GCV therapy demonstrates bystander effects in a number of models. Numerous studies have shown this is mediated primarily by gap junctional intercellular communication (GJIC) \[[@B7], [@B12], [@B13]\]. Because extensive gap junction networks are not common in tumors, a variety of methods to augment HSV-Tk/GCV therapy have been explored \[[@B7]\]. There is also extensive evidence of an immunological component to the bystander effect in vivo, in that along with the regression of HSV-*tk* transduced tumors, distant nontransduced tumors also show significant effects \[[@B14]\]. A T~H~1-based immune response was seen in rat prostate cancer models undergoing HSV-Tk/GCV therapy \[[@B15]\], and a clinical study also showed elevated numbers of peripheral T and B cells, enhanced T-cell activation, and elevated serum levels of interleukin 12 during intracranial GCV treatment \[[@B16]\].

The major clinical use of GCV in GDEPT has been in glioblastoma, using direct injection of the tumor with the vector, followed by systemic administration of prodrug. The drug is well-tolerated, but there have been varied reports of its utility, including a recent large multicenter stage-III trial on 248 patients with newly diagnosed, previously untreated glioblastoma multiforme \[[@B17]\]. This trial found no benefit in either time to tumor progression nor overall survival time compared to best available therapy (surgical resection and radiotherapy), attributed to the poor rate of delivery of the HSV-*tk* gene, and possibly poor delivery of the prodrug across the blood-brain and blood-tumor barriers.

Another approach to improving therapy with GCV is the use of mutant enzymes. Several studies have showed that random \[[@B18]\] or semirandom \[[@B19]\] mutagenesis of the wild-type enzyme can provide substantial increases in both in vitro and in vivo activity, allowing lower and less immunosuppressive doses of GCV to be used. A number of mutation sites (eg, at Gln-125 and Ala-168) result in higher Km values for thymidine binding due to loss of H-bond contacts, and unaltered or even improved binding for GCV \[[@B20], [@B21]\]. This results in reduced competition between prodrug and thymidine at the active site, providing improved kinetics of conversion of GCV.

Combination therapy with HSV-Tk/GCV and other agents have also been explored. Some of these, like proteases such as trypsin or collagenase/dispase \[[@B22]\] are designed to improve gene delivery. Others are designed to complement the effects of the activated drug, such as stimulation of the immune system with GM-CSF in \[[@B23]\], which showed increased cure rates in animal models. Radiation therapy has been used both to upregulate promotors to increase gene expression \[[@B24]\] and to enhance the cytotoxicity of the activated drug \[[@B25]\]. In HSV-Tk transduced mouse RM-1 prostate cancer cells, the combination of GCV and radiation was additive at low doses of radiation, and possibly synergistic above doses of 8 Gy \[[@B26]\]. Retinoids increase GJIC by induction of connexin expression, and augment the efficiency of cell killing by GCV in HSV-YK transduced cell lines \[[@B27]\].

A variety of thymidylate synthase inhibitors, including Tomudex, 5-fluorouracil (5-FU) and (E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU) show synergistic cell killing when used with GCV in clonogenic assay studies, while a combination of GCV and 5-FU provided significantly-enhanced survival rates in an sc HT-29 STK tumor xenograft model in mice \[[@B28]\]. Combinations of GCV and the topoisomerase I inhibitor topotecan also showed synergistic cell killing in HSV-Tk transduced murine MC38 and human HT-29 colon carcinoma cell lines in a clonogenic assay, and were superior to GCV alone in sc tumor xenograft models using the same cell lines in athymic nude mice \[[@B29]\].

Ganciclovir elaidic acid ester (E-GCV; 2a)
------------------------------------------

This very lipophilic (log P + 7.0) preprodrug of GCV is more potent than GCV itself in cell cultures (EC~50~ for E-GVC around 2 nmol), with a selectivity index (IC~50~ ratio) in FM3Atk-/HSV-1tk+ cells of \> 2000 fold. Nonspecific hydrolysis of the ester gives GCV, and both GCV and E-GCV were converted to the mono-, di-, and triphosphates of GCV. However, the half-lives of both GCV and its phosphate metabolites were much longer (about 50 hours) in cells treated with E-GCV rather than GCV, suggesting the possible utility of lipophilic preprodrugs for modulating pharmacokinetics \[[@B30]\].

Penciclovir (PCV; 3a)
---------------------

This prodrug is closely related to GVC, with the ether replaced by a CH~2~ group, and has similarly low lipophilicity (log P − 2.03). PCV is less genoxic than GCV or ACV, inducing sister chromatid exchanges only at cytotoxic/apoptotic concentrations, and is only weakly clastogenic \[[@B11]\]. Treatment of HSV-Tk transformed baby hamster kidney cells with PCV and GCV, but not ACV, induced rapid accumulation of cells in the S-phase and apoptotic death as measured by the TUNEL assay \[[@B31]\], and this property, together with the low genotoxicity of PCV, makes it a relatively safe alternative drug for suicide gene therapy \[[@B32]\].

Acyclovir (ACV; 4a)
-------------------

As Zovirax, ACV is the most frequently used antiherpes drug. It is closely-related chemically to GCV, but is slightly more lipophilic (log P − 1.76) due to one less alcohol group. ACV is a moderate genotoxin in CHO cells, inducing chromosomal aberrations and sister chromatid exchange but only at concentrations much higher than those achieved in blood plasma in vivo \[[@B11]\]. Comparative studies have generally shown it to be an effective prodrug for HSV-Tk, both less toxic and less potent and (perhaps surprisingly in view of its higher lipophilicity) with lower bystander effects. However, in a study using ovarian cancer cell lines and comparing ACV and GCV at equal concentrations, the former showed equal or higher cell killing efficacy and bystander effects \[[@B33]\]. In other studies using U251tk human glioblastoma cells stably expressing HSV-Tk, ACV gave a lesser cell kill than did GCV (\< 1.5 log compared to \> 4 log) \[[@B10]\]. As with GCV, ACV sensitizes HSV-Tk transduced cells to radiation \[[@B34]\]. Clinical studies of patients with recurrent ovarian cancer treated with a replication-deficient HSV-*tk* gene vector, ACV and the topoisomerase I inhibitor topotecan showed median overall survival comparable to that of patients treated with conventional chemotherapy \[[@B35]\].

Valacyclovir (VCV; 5a)
----------------------

Valacyclovir is a valine ester preprodrug form of ACV, which can be given orally. It is relatively lipophilic, although partial ionization of the amine counteracts this to some extent (log D~7~ = −0.78). In a clinical study of recurrent ovarian cancer treated with an IP-injected HSV-*tk* vector followed by topotecan and either IV ACV or oral VCV, the levels of ACV and VCV (measured as released ACV) were similar, suggesting the use of VCV as a cost-effective alternative in outpatient therapy \[[@B36]\]. Clinical trials of VCV and a locally-injected replication-deficient HSV-*tk* vector in prostate cancer, with \[[@B37]\] or without \[[@B38]\] concomitant radiation therapy, are in progress.

(E)-5-(2-bromovinyl)-2′-deoxyuridine (BVDU; 6a)
-----------------------------------------------

This is a potent antiherpes agent recently also used as a prodrug in gene therapy, and is considerably more lipophilic than GCV (log P = −0.43). An efficient synthesis has been reported \[[@B39]\]. BVDU exerts its cytotoxic effect not only by incorporation into replicating DNA, but also through inhibition of thymidylate synthase. It enhances the GCV-induced killing of HSV-Tk transduced glioma cells \[[@B40]\], although BVDU itself is reported to have a poor bystander effect, both in vitro \[[@B41], [@B42]\] and in vivo \[[@B43]\]. It is a particularly good substrate for the varicella zoster virus thymidine kinase (VSV-Tk). While GCV was not toxic in VSV-Tk transduced MCF7, T-47D, and MDA-MB-435 breast cancer cells, BVDU showed high cytotoxicity (IC~50~s 600, 100, and 60 nmol, respectively) and selectivity indices (IC~50~ ratios of wild-type to VZV-Tk cells of 400, 750, and 2000, respectively). Bystander effects were not observed in vitro in MDA-MB-435 cells, but were seen in 9L rat gliosarcoma cells \[[@B44]\]. BVDU showed radiosensitizing activity in U-251 human glioma cells transduced with HSV-Tk, giving a sensitization enhancement ratio of 1.9.

Zidovudine (AZT; 7a)
--------------------

While the anti-AIDS drug AZT is a relatively poor substrate for HSV-Tk, its antimetabolite-type mechanism of action is similar to that of the guanosine analogues antiherpes drugs discussed above, and its lipophilicity is (log P − 0.58) similar to that of BVDU. Genetic modification of HSV-Tk produced mutants with reduced specificity for thymidine and much greater ability to phosphorylate AZT, due to active site mutations that better accommodate the azido group of AZT at the expense of thymidine \[[@B45]\].

2′-Exo-methanocarbathymidine (MCT; 8a)
--------------------------------------

The potent antiviral drug MCT is a substrate for HSV1-Tk \[[@B46]\], but a better one (12-fold increase in K~M~) for the Y101F mutant. Crystal structure studies \[[@B47]\] of MCT with both enzymes show that the thymine moiety of MCT binds similarly to deoxythymidine, with the conformationally restricted bicyclo\[3.1.0\]hexane mimicking the sugar moiety. In MC38/HSV1-Tk murine colon cancer cells, MCT had an IC~5~ of 2.9 μmol (comparable to that of GCV), and was metabolized to the mono-, di-, and triphosphates. Treatment of MC38/HSV1-Tk tumors in C57/BL6 mice at 100 mg/kg twice daily caused complete inhibition of tumor growth \[[@B48]\].

PRODRUGS FOR CYTOSINE DEAMINASE (CD)
====================================

Introduction
------------

After HSV-Tk, the cytosine deaminase gene is the next most widely studied for GDEPT. The enzyme (CD) encoded by this gene catalyzes the conversion of cytosine to uracil, and is an important member of the pyrimidine salvage pathway in prokaryotes and fungi, but is not present in multicellular eukaryotes. The crystal structure of *E. coli* CD has an αβ-8 barrel structure with similarity (structurally not sequence) to adenosine deaminase, but not to cytidine deaminase \[[@B49]\]. The enzyme is a hexamer, stabilized by domain swapping between enzyme subunits, and containing the active site in the mouth of the enzyme barrel. GDEPT therapy using CD has focused almost entirely on one prodrug, the clinically used antifungal agent 5-fluorocytosine.

5-Fluorocytosine (5-FC; 9a)
---------------------------

5-Fluorocytosine is a relatively hydrophilic (log P −1.79) antifungal agent with low toxicity in humans, who lack an endogenous enzyme that can activate it efficiently. However, bacterial and yeast CD enzymes convert it efficiently to 5-fluorouracil (5-FU) (**9b**). Studies with tritiated-5-FC in a human glioblastoma cell line stably transfected with the *E. coli* gene for CD showed it entered the cells relatively slowly by passive diffusion, and showed rapid efflux, suggesting that transport of this quite hydrophilic prodrug may be a limiting factor \[[@B50]\]. The active form 5-FC is also quite polar (log D~7~ − 2.29) but is a diffusible species that is itself the single most effective drug for colon cancer, being converted by cellular enzymes to the ribosyl monophosphate 5-FdUMP ([Figure 3](#F3){ref-type="fig"}), which is an irreversible inhibitor of thymidylate synthetase. An NMR study of 5-FC in sc yeast CD-transfected human colorectal carcinoma xenografts in nude mice derived rate constants of 0.49 min^−1^ for CD-catalyzed prodrug conversion and 0.77 min^−1^ for 5-FU efflux from the tumor volume \[[@B51]\]. In contrast to GCV, the bystander effects of CD/5-FC therapy do not depend on gap junctional intercellular communication (GJIC), and very large effects are seen with both communication-competent and -incompetent cells \[[@B52]\], mediated by the diffusion of 5-FU. It has been suggested that CD/5-FU therapy in solid tumor models can generate complete cures if only 4% of the tumor cell mass express the enzyme \[[@B53]\].

CD/5-FC therapy has been studied, usually with the *E. coli* enzyme, in a wide variety of cancers, perhaps most notably colon using the carcinoembryonic antigen (CEA) promoter \[[@B53], [@B54]\]. MDA-MB-231 breast carcinoma cells transfected with *E. coli* CD were sensitized 1000 fold to 5-FC in culture, with only 10% of the infected cells needed to induce complete cytotoxicity of in cocultures with noninfected cells. Sc MDA-MB-231 breast carcinoma xenografts in nude mice \[[@B55]\] and intracranial human glioma xenografts in scid mice \[[@B56]\] were controlled by an intratumoral dose of an adenovirus encoding *E. coli* CD and systemic 5-FU. Similar studies have shown the utility of CD/5-FC in hepatic metastases of colon carcinoma \[[@B57]\] and prostate cancer \[[@B58]\]. Studies using Saccharomyces cerevisiae CD, which has a K~M~ for 5-FC about 22-fold lower than that of *E. coli* CD show that this enzyme also shows superior results in sc HT29 human colon carcinoma xenografts \[[@B59]\], producing about 15-fold more 5-FU in tumors at the same dose of 5-FC and greater radiosensitization \[[@B60]\]. When 5-FC/CD and HSV-Tk/GCV therapies were compared in a variety of in vivo models, both appeared of similar efficacy in hepatocellular carcinoma \[[@B61]\], but CD/5-FC was clearly superior in EBV-associated lymphomas \[[@B62]\], renal cell carcinoma \[[@B63]\], and colorectal carcinoma \[[@B64]\], attributed to its superior bystander effect.

Coexpression of CD together with *E. coli* uracil phosphoribosyltransferase (UPRT), which is absent in mammalian cells and which directly converts 5-FU to the 5′-monophosphate (5′-FdUMP), is synergistic. 9L glioma cells expressing both enzymes were 375-fold more sensitive to 5-FC than cells transduced with CD alone \[[@B65]\]. Cells expressing both enzymes showed large increases in 5-FdUMP, 5-fluorouridine triphosphate, incorporation into RNA and inhibition of thymidylate synthase \[[@B66]\]. Coexpression of both CD and HSV-Tk enzymes was also shown to be synergistic, both in vitro \[[@B68]\] and in sc rat 9L glioma tumors in nude mice \[[@B67]\] treated with 5-FC and GCV. The mechanism appears to be an enhancement of GCV phosphorylation by HSV-Tk following 5-FC treatment \[[@B68]\].

Combination studies of 5-FC with radiotherapy in CD-transfected tumors also show sensitization of sc xenografts of squamous cell carcinoma \[[@B69]\], cholangiocarcinoma \[[@B70]\] and colon carcinoma \[[@B71]\], using a dose of 800 mg/kg/day of 5-FC and from 10--50 Gy of tumor irradiation. Dose-modifying factors of up to 1.5 were observed. A Phase I clinical trial of CD linked to a tumor-specific erbB2 promotor in breast cancer patients showed significant levels of expression of the CD gene, restricted to erbB-2-positive tumor cells, in about 90% of cases \[[@B72]\].

PRODRUGS FOR PURINE NUCLEOSIDE PHOSPHORYLASE (PNP)
==================================================

Introduction
------------

The *E. coli* purine nucleoside phosphorylase (PNP) is a hexameric enzyme that catalyzes the reversible phosphorolysis of 6-amino-2′-deoxyribonucleosides to the free base and 2′-deoxyribose-1-phosphates, whereas the corresponding (trimeric) human enzyme only hydrolyses 6-oxopurine nucleosides. Comparative crystal structures show that the active-site location and its overall geometry are similar for the *E. coli* and human enzymes, but the subunit interactions are quite different, with the *E. coli* enzyme having more hydrophobic purine- and ribose-binding sites \[[@B73]\].

6-Methylpurine deoxyriboside (MEP; 10a)
---------------------------------------

The most widely used prodrug for PNP in GDEPT is 6-methylpurine deoxyriboside (MEP) (log D~7~ − 0.35), which is converted by PNP to more lipophilic (log D~7~ − 0.09) and highly diffusible metabolite **10b** ([Figure 4](#F4){ref-type="fig"}). This has the potential advantages of being less cell cycle-specific than most antimetabolites and having excellent bystander effects. Human ovarian tumors transfected with *E. coli* PNP controlled by an SV40 promoter and implanted IP were shown to express PNP in only 0.1% of the cells after 5 days, yet treatment of these with MEP resulted in an average 49% reduction in tumor size and 30% increase in life span compared with control tumors \[[@B74]\]. A comparison of MEP/PNP and GCV/HSV-Tk therapy in a PC-3 human androgen-independent prostate cancer cell line showed that MEP/PNP caused more rapid cell killing at a 5--10-fold lower input of virus \[[@B75]\]. Against the same cells as sc tumors in nude mice, both systems showed comparable activity, holding tumor growth to about 75% of that of controls after 52 days, and providing about 20% of long-term survivors \[[@B76]\].

Fludarabine (FAMP; 11a)
-----------------------

Fludarabine (arabinofuranosyl-2-fluoroadenine mono phosphate), has also been studied as a possible prodrug for PNP gene therapy. FAMP showed good activity against sc D54MG glioma tumor xenografts expressing *E. coli* PNP, but was not quite as effective as MEP \[[@B77]\]. Human hepatocellular carcinoma cell lines (HepG2, Hep3B, and HuH-7) expressing PNP were highly sensitized to FAMP, showing IC~50~s of \< 1 μmol, with excellent bystander effects (better than those for GCV) \[[@B78]\]. Treatment of PNP-transduced HepG2 and Hep3B cells with FAMP induced p53 accumulation and the rapid onset of apoptosis, and caused similar levels of killing in both p53-positive and negative lines. This independence of FAMP-induced killing on p53 status suggests that FAMP/PNP may be superior to GCV/HSV-Tk for gene therapy of human hepatocellular carcinoma \[[@B79]\].

PRODRUGS FOR CYP ENZYMES
========================

Introduction
------------

Prodrugs for gene therapy based on NADH cyto-chrome P450 (CYP) enzymes are compounds that are normally activated primarily by one or more of the many CYP isozymes \[[@B80]\]. The large number of different isozymes, and the fact that many drugs and other xenobiotics are metabolized by them, makes the potential choice of prodrugs quite wide. Many of these enzymes are expressed to greater extent in liver than in tumor cells, so the primary goal of this strategy is to selectively increase tumor cell exposure to cytotoxic drug metabolites by targeting expression of the enzymes to tumor cells by gene vectors. To date, this area has been dominated by only two prodrugs, the alkylating agents cyclophosphamide and ifosfamide, but the range of potential compounds is expanding.

Cyclophosphamide (CPA; 12a)
---------------------------

This is the most widely used alkylating agent in conventional cancer chemotherapy. It is much more lipophilic than the majority of the antimetabolites discussed above (log P + 0.23) and works by a different mechanism. It is converted to the active alkylating agent phosphoramide mustard (**12b**) via initial hydroxylation to 4-hydroxycyclophosphamide (hydroxy-CPA) by CYP enzymes (primarily CYP2B1) in the liver (tumor cells generally contain only low levels of enzyme). Hydroxy-CPA is in equilibrium with the open-chain aldophosphamide, which undergoes spontaneous elimination to give acrolein and phosphoramide mustard ([Figure 5a](#F5){ref-type="fig"}). Phosphoramide mustard is a DNA cross-linking agent that kills cells in a largely cell cycle-independent manner, and thus CPA has potential advantages over GCV and 5-FC, which are cell cycle-specific agents. While phosphoramide mustard itself is very polar (log D~7~ − 3.95), the more lipophilic intermediate CPA metabolites (primarily hydroxy-CPA) do not require cell-cell contact for a bystander effect, distributing by passive diffusion \[[@B81], [@B82]\]. Early studies with CPA in gene therapy utilized both retroviral- and adenoviral-mediated transduction of glioma cells with CYP2B1, and showed that this sensitized them to CPA both in vitro \[[@B83]\] and in vivo \[[@B81]\]. Protection of transduced cells from CPA-induced cytotoxicity with the CYP2B1 enzyme inhibitor metyrapone showed that this sensitization was a direct consequence of intracellular prodrug activation \[[@B81]\]. Since CYP-catalyzed drug metabolism is dependent on electron transfer from the flavoenzyme NADPH-P450 reductase, double transduction of rat 9L glioma cells with both enzymes substantially increased tumor cell killing \[[@B84]\], and inhibitors of NADPH-P450 reductase inhibited the activation of CPA by CYP enzymes \[[@B85], [@B86]\].

The use of other CYP isozymes to activate CPA has been explored. AHH-1 human lymphoblastoid cells transfected with CYP2C9 were 5-fold sensitized to CPA compared with the wild-type line (IC~50~s 0.80 and 4.1 mmol, respectively), and showed a bystander killing effect. This sensitivity was blocked by the CYP2C9-specific inhibitor sulfaphenazole. While the sensitivity enhancement is not large, CYP2C9 and CPA may possibly be useful for GDEPT \[[@B87]\]. In a comparative study, 9L-rat glioma cells were transfected with six different CYP enzymes; 2B6, 2C8, 2C9, 2C18 (Met385 and Thr385 alleles), 2C19, and 3A4 \[[@B88]\]. Greatest sensitization to CPA was seen with CYP2B6, but CYP2C18-Met was also effective, despite a very low level of CYP protein expression (\> 60-fold lower than that of 2B6), with substantial further increases upon additional transduction with NADH P450 reductase. In 9L glioma sc tumors transduced with 2B6 or 2C18-Met in immunodeficient mice, the best effects were seen with concomitant expression of NADH P450 reductase (growth delays of 25--50 days, compared with 5--6 days). Transduction of HT29 and T47D human colon carcinoma cells with CYP2B6 using a retroviral vector (MetXia-P450) sensitized these cells to CPA, and produced a substantial bystander effect in 3-D multicellular spheroid models \[[@B89]\]. Treatment of scid mice bearing 400 mm^3^ sc tumors from 9L glioma cells transduced with CYP2B6 and NADHP450 reductase with CPA (140 mg/kg every 6 days) achieved eradication of 6 out of 8 tumors. With larger tumors, some resistance to CPA was seen, involving loss of expression of the genes \[[@B90]\].

Ifosfamide (IFO; 13a)
---------------------

Ifosfamide is also used clinically as a conventional anticancer drug. It is closely related both chemically and mechanistically to cyclophosphamide, having similar lipophilicity (log P + 0.50) and releasing the same ultimate metabolite, phosphoramide mustard (**12b**) ([Figure 5a](#F5){ref-type="fig"}). Feline kidney cells transfected with CYP2B1 were sensitized to IFO, and killed via necrotic rather than apoptotic mechanisms \[[@B91]\]. When these cells also expressed cytosine deaminase, additive killing was seen with combinations of both IFO and 5-FU \[[@B92]\]. CYP2B1-transduced human embryonic epithelial cells implanted in mice bearing human PaCa-44 pancreatic tumor xenografts sensitized these to IP IFO, resulting in partial or even complete tumor ablation \[[@B93]\]. 9L glioma cells transduced with CYP2B6 and NADPH P450 reductase were sensitized to both CPA and the bioreductive drug tirapazamine (TPZ) to the same extent under both normoxic (20% O~2~) and hypoxic (1% O~2~) conditions \[[@B94]\]. Under hypoxia, both CPA and TPZ showed bystander effects, which is surprizingly given the nature of the highly reactive radical intermediate thought to be the active species of TPZ.

Acetaminophen (14a)
-------------------

The widely used and relatively lipophilic (log P + 0.34) anti-inflammatory drug acetaminophen is oxidized by the human CYP1A2 enzyme to the cytotoxic metabolite N-acetylbenzoquinoneimine (NABQI; **14b**) ([Figure 5b](#F5){ref-type="fig"}), which is the major source of toxicity of this drug. Transfection of H1A2 MZ cells with human CYP1A2 sensitized them to treatment with acetaminophen, with the generation of a substantial bystander effect (complete killing of V79 cells in a mixture containing 5% transduced H1A2 MZ cells) \[[@B95]\]. Similar bystander effects were seen with transduced SK-OV-3 human ovarian tumor cells and HCT116 human colon tumor cells, but not with MDA-MB-361 breast tumor cells. Acetaminophen is thus a possible prodrug for GDEPT in conjunction with CYP1A2.

4-Ipomeanol (4-IM; 15a)
-----------------------

4-Ipomeanol is a relatively lipophilic furoketone (log P + 0.70) that is efficiently converted by the rabbit CYP4B1 enzyme, but not by the corresponding human isozyme, into toxic DNA-alkylating metabolites of unreported structure \[[@B96]\]. Both rat (9L) and human (U87) glioma cell lines transduced with rabbit CYP4B1 were sensitized about 20 fold to 4-IM (IC~50~s about 2.5 μmol), with an efficient bystander effect. Cell killing was associated with DNA fragmentation (TUNEL assays) and extensive protein-DNA crosslinking and single-strand breaks. In 9L sc tumor xenografts in nude mice, 4-IM induced significant growth delays. Similar results were seen in a range of human hepatocellular carcinoma cell lines (Hep3B, HuH-7, and HepG2) transduced with rabbit CYP4B1 and treated with 4-IM, except that bystander effects seemed to be cell-specific \[[@B97]\]. In a further comparative study \[[@B98]\], 4-IM treatment of CYP4B1-transduced 9L glioma cells showed very little bystander effect (much less than that shown by GVC/HSV-Tk). Thus the utility of 4-IM for GDEPT needs further clarification.

PRODRUGS FOR CARBOXYPEPTIDASES (CP)
===================================

Introduction
------------

This enzyme, from various species of *Pseudomonas* bacteria, and for which there is no mammalian counterpart, has been investigated for use in gene therapy because of its ability to cleave glutamate moieties \[[@B99]\]. Because the substrates for this enzyme are necessarily diacids, it has been used primarily in ADEPT protocols, where cell exclusion of very polar prodrugs until activation is an added benefit. However, more recently it has been adapted for use in GDEPT by being engineered for surface expression on the cells \[[@B100]\].

4-\[(2-chloroethyl)(2-mesyloxyethyl)amino\]benzoyl-L-glutamic acid (CMDA; 16a)
------------------------------------------------------------------------------

The very polar (log D~7~ − 4.67) "mixed" chloromesylate mustard CMDA was first studied as a prodrug for ADEPT, in conjunction with the enzyme carboxypeptidase G2 (CPG2) derived from the bacterium *Pseudomonas putida*, which cleaves the glutamate to generate the active carboxylic acid species **16b** ([Figure 6a](#F6){ref-type="fig"}) \[[@B99]\]. However, studies with human adenocarcinoma cell lines (A2780 and SK-OV-3) and human colon carcinoma cell lines (LS174T and WiDr) that expressed CPG2 internally showed enhanced sensitivity to CMDA over control lines (11--16 fold for WiDr and SK-OV-3, 95 fold for A2780 and LS174T), showing these diacids do enter cells \[[@B100]\]. Complete cell killing was achieved with 4--12% of cells expressing the enzyme, indicating a substantial bystander effect from the much more lipophilic (log P + 0.05) released aniline mustard effector **16b**. Nevertheless, later work comparing CMDA with internally-expressed and surface-tethered CPG2 enzymes in the A2780, SK-OV-3, and WiDr cell lines showed the latter was superior for activating CMDA \[[@B101]\]. Lower levels of enzyme and shorter exposures to prodrug were required for cell killing with surface-tethered compared to internally-expressed CPG2. The activity of CMDA against human MDA-MB-361 breast carcinoma xenografts in nude mice correlated with the percentage of CPG2-expressing cells, with some cures seen even with tumors containing 50% wild-type cells, confirming a substantial bystander effect \[[@B102]\].

Hydroxy- and amino-aniline mustards (eg, 17a and 18a)
-----------------------------------------------------

Because the effector **16b** released from CMDA is only a moderately potent cytotoxin (IC~50~ 65 μm in LS174T human colon carcinoma cells \[[@B103]\]), more potent effectors have been sought. Thus the prodrugs **17a** and **18a** release effectors (**17b** and **18b**; [Figure 6a](#F6){ref-type="fig"}) that are up to 70-fold more potent than **16b** (IC~50~s in LoVo colon carcinoma cells of 1.8 μmol and 0.34 μmol, respectively) \[[@B103], [@B104]\]. These prodrugs showed IC~50~ differentials of 12--14 fold between wild-type and surface CPG2-expressing WiDr human colon tumor cell lines in culture. The iodomustard glutamate prodrug **18a**, already in clinical trial as a prodrug for ADEPT \[[@B105]\], also showed much greater IC~50~ differentials in surface CPG2-expressing MDA-MB-361 and WiDr cells than did CMDA (70--450 fold compared to 19--27 fold), and was highly effective against the MDA-MB-361 xenografts in nude mice \[[@B106]\].

Anthracycline glutamates
------------------------

Prodrugs of anthracycline topoisomerase inhibitors such as doxorubin with glutamate residues directly attached to the glycoside nitrogen were not substrates for CPG2, so analogues with a 4-benzylcarbamate spacer group were investigated \[[@B107]\]. These prodrugs (eg, **19a**) undergo 1,6-elimination following cleavage of the glutamate by CPG2 to release doxorubicin (**19b**) ([Figure 6b](#F6){ref-type="fig"}). MDA-MB-361 breast cancer cell lines expressing CPG2 intracellularly or tethered to the outer cell membrane showed about a 10-fold IC~50~ differential compared to wild-type cells \[[@B107]\].

Methotrexate α-peptides (MTX-Phe; 20a)
--------------------------------------

Methotrexate-α-peptides (eg, MTX-Phe; **20a**) are prodrugs of methotrexate (MTX; **20b**), a potent inhibitor of dihydrofolate reductase, and a widely used anticancer drug. Unlike MTX, the prodrugs are poor substrates for the reduced folate carrier, and thus not taken up by cells, but can be cleaved to methotrexate by carboxypeptidase A1 (CPGA) ([Figure 6c](#F6){ref-type="fig"}) \[[@B108]\]. This endogenous enzyme is normally inactive until trypsin proteolysis of its propeptide, but a mutant form (CPAST3), activated by ubiquitously expressed intracellular propeptidases, has similar prodrug activating properties \[[@B109]\]. Tumor cells retrovirally transfected with a cell surface tethered version of CPAST3 were highly sensitized to MTX-Phe, which also showed an efficient bystander effect (complete cell kill with \< 10% of the cells transduced).

PRODRUGS FOR CARBOXYLESTERASE (CE)
==================================

Introduction
------------

The group of enzymes known as carboxylesterases hydrolyse esters and some carbamates to their component acids and alcohols, and are known to activate some clinical anticancer drugs, notably irinotecan \[[@B110]\] and KW-2189 \[[@B111]\].

Irinotecan (IRT; 21a)
---------------------

Irinotecan is a lipophilic (log D~7~ = 1.54) topo I inhibitor that has been used widely clinically as an anticancer drug. It is converted to the active form SN-38 (7-ethyl-10-hydroxycamptothecin, **21b**) in humans primarily by carboxylesterase ([Figure 7a](#F7){ref-type="fig"}). However, human CE is relatively poor at activating IRT, with rabbit liver CE being 100--1000-fold more efficient \[[@B110]\]. A 549 human lung adenocarcinoma cells transfected with the human carboxylesterase gene driven by the CMV promoter were able to convert IRT to the active metabolite SN-38, which showed a substantial bystander effect in cell culture \[[@B112]\]. When the construct was injected directly into established sc A549 tumors in nude mice, treatment with IRT resulted in 30--40% reductions in tumor size compared with controls. A panel of human tumor cell lines transduced with rabbit liver CE showed high levels of CE activity, and were sensitized by 11--127 fold to IRT \[[@B110]\]. This protocol has been studied as a potential purging method in autologous stem cell rescue for neuroblastoma. Transfection of neuroblastoma cell lines (SJNB-1, NB-1691, and SK-N-SH) by a replication-deficient adenoviral construct containing rabbit CE resulted in 100% transfection, and sensitized the cells to IRT by 20--50 fold \[[@B113]\].

Anthracycline acetals (22a)
---------------------------

The lipophilic doxorubicin acetal (**22a**) (log D~7~ + 2.04) is a substrate for CE, which hydrolyses it to an intermediate hemiacetal that undergoes immediate cyclization to the cyclic carbinolamine (**22b**) ([Figure 7b](#F7){ref-type="fig"}) \[[@B114]\]. These anthracycline carbinolamines (or more likely the resultant iminium ion; [Figure 7b](#F7){ref-type="fig"}) are known to be extremely cytotoxic agents (100--1000-fold more potent than doxorubicin itself), probably due to covalent interaction with DNA. However, the system does not appear to have been evaluated in CE-transfected cell lines, and it is likely that compounds like **22a** are too unstable to act as tumor-specific prodrugs.

PRODRUGS FOR NITROREDUCTASE (NTR)
=================================

Introduction
------------

Enzymes that metabolize aromatic nitro groups are attractive for GDEPT because of the very large electronic change that this metabolism generates. Metabolism of a nitro group (Hammett σ~p~ electronic parameter = 0.78) to the corresponding hydroxylamine 4-electron reduction product (σ~p~ = −0.34) that is normally the major metabolite, or the possible amine 6-electron reduction product (σ~p~ = −0.66) ([Figure 1](#F1){ref-type="fig"}). These are among the largest possible increases in the electronic effect (Δσ = 1.12 and 1.44) that can be achieved in a single metabolic step \[[@B115]\], and this substantial change in electron distribution in the prodrug can be exploited in a variety of ways to activate the effector. Nearly, all GDEPT studies with nitroreductases have used the nfsB gene product of *E. coli*, an oxygen-insensitive flavin mononucleotide (FMN)-containing nitroreductase (NTR) \[[@B116]\], with a close sequence homology to the classical nitroreductase of *S. typhimurium* \[[@B117]\]. Crystal structure determinations of NTR show it to be a homodimer with one FMN per monomer, with two channels leading into the active site \[[@B118]\]. There are relatively few contacts made with the ligand, which may contribute to its observed broad substrate specificity \[[@B119]\]. NTR efficiently reduces aromatic nitro groups to the hydroxylamines in a two-step ping pong bi-bi mechanism \[[@B118]\]. Four broad classes of prodrugs for NTR have been studied; dinitroaziridinylbenzamides, dinitrobenzamide mustards, 4-nitrobenzylcarbamates, and nitroindolines, and most work has been done with the dinitroaziridinylbenzamide CB1954.

CB1954 (23a)
------------

The dinitroaziridinylbenzamide CB1954 (**23a**) is a relatively lipophilic (log P + 1.54) prodrug that is efficiently reduced by NTR (k~cat~ = 360 min^−1^) \[[@B117]\], effecting reduction of either the 4- or 2-nitro groups to the corresponding hydroxylamines at about equal rates ([Figure 8a](#F8){ref-type="fig"}). Modelling suggests that the small aziridine residue allows the drug far enough into the binding pocket that both the 2- and 4-nitro groups have access to the FMN \[[@B118]\]. The 4- hydroxylamine (**23b**) is then further metabolized by cellular acetylation pathways to a cytotoxic DNA interstrand-crosslinking agent \[[@B120]\] ([Figure 8a](#F8){ref-type="fig"}). CB1954 demonstrates substantial bystander effects \[[@B121]\], due to the cell-permeable hydroxylamine metabolite (log P − 0.34) \[[@B122]\]. CB1954 shows high selectivity (100--2000 fold) in a variety of NTR-transfected cell lines, including human ovarian (SKOV-3) \[[@B123]\], colorectal (LS174T), and pancreatic (SUIT2, BxPC3) \[[@B124]\], with sensitivity correlating closely with the level of NTR enzyme expression \[[@B123]\].

B1954 also showed excellent bystander effects in vivo, inducing long growth delays of human hepatocellular carcinoma and squamous carcinoma xenografts, even when only a minority of the tumor cells expressed the enzyme \[[@B125]\]. Treatment of scid mice with Burkitt lymphoma (Jijoye) tumors containing 30% NTR-expressing cells with CB1954 at 20 mg/kg/day for 10 days also gave growth inhibition, suggesting a substantial bystander effect \[[@B126]\]. However, expression of NTR in the luminal cells of the mammary gland using the ovine β-lactoglobulin promoter resulted in rapid and selective killing of this cell population by CB1954 with minimal effects neighbouring myoepithelial cells, suggesting that the toxic metabolite does have a finite diffusion range \[[@B127]\].

A Phase I clinical trial of CB1954 without NTR, administered IV on a 3-weekly cycle, determined a recommended IV dose of 24 mg/m^2^. Dose-limiting toxicities at 37.5 mg/m^2^ were diarrhoea and elevation of liver transaminases, but no marrow suppression or nephrotoxicity. A Phase I clinical trial of CB1954 in combination with adenovirus-delivered NTR is in progress in patients with primary and secondary liver cancer \[[@B128]\].

SN23862 (24a) and analogues
---------------------------

The dinitrobenzamide mustard SN23862 is more lipophilic than CB1954 (log P = 2.06), and a better substrate for NTR (K~cat~ 1580 min^−1^) \[[@B129]\]. Unlike CB1954, only the 2-nitro group is reduced (possibly because the larger mustard unit restricts drug entry to the active site of NTR) to give the lipophilic (log P = 2.50) 2-hydroxylamine (**24b**) ([Figure 8b](#F8){ref-type="fig"}) \[[@B130]\]. The initial reductive step fully activates the mustard for DNA crosslinking without further metabolism. While mammalian enzymes with nitoreductase activities exist, in rats, the major endogenous reductive pathway is via the 4-nitro group, giving the 4-hydroxylamine (**25**) and ultimately the relatively nonpotent tetrahydroquinoxaline (**26**) as the major metabolite ([Figure 8b](#F8){ref-type="fig"}) \[[@B131]\]. SN23862 \[[@B132]\] and other mustard analogues \[[@B133]\] are also not substrates for endogenous DT diaphorase, increasing their attractiveness as NTR prodrugs.

A recent study \[[@B4]\] of a series of analogues of **23a** and **24a** demonstrated good correlations between the lipophilicities of the parent prodrugs (measured log P values) and their bystander effects, measured in both 3-D cell multilayer cocultures of NTR+ve and NTR−ve V79 and WiDR cells, and also in mixed NTR+ve/NTR−ve WiDr tumors in nude mice. This study provides quantitative evidence, in a series of close analogues, of the importance of lipophilicity in determining the level of bystander effect; analogues with log P values lower than that of CB1954 showed relatively poor bystander effects.

In a series of analogues of SN23862 where the 4-nitro group was replaced by other substituents of varying electronic properties, cytotoxicity in UV4 cell cultures, from added NTR enzyme, correlated roughly with the electron-withdrawing properties of the 4-substituent \[[@B134]\]. The 2-amino-3, 5-dinitrobenzamide regioisomer (**27a**) of SN23862 was also a substrate for NTR, and was in fact superior, with a k~cat~ of 4540 min^−1^ \[[@B129]\]. Comparative cell line studies with SN23862 and the regioisomers **27a** and **28a** in NTR-transfected Chinese hamster-derived cell lines showed that regioisomeric changes are permitted, with the all three retaining selective cytotoxicity. Finally, analogues with other leaving groups (bromo- and iodo-mustards) retain good selectivity for the NTR-transfected line together with higher potency \[[@B135]\].

4-Nitrobenzyl carbamates
------------------------

Despite their low reduction potential of around −490 mV \[[@B136]\], 4-nitrobenzyl carbamates are substrates for NTR, being reduced to the hydroxylamines which then undergo spontaneous fragmentation to release an amine-based effector ([Figure 9](#F9){ref-type="fig"}) \[[@B137]\]. Electron-donating substituents on the benzyl ring accelerate the fragmentation step \[[@B138]\]. This system is theoretically very flexible, and 4-nitrobenzyl carbamates of a number of different classes of cytotoxic amines have been explored as potential GDEPT prodrugs \[[@B139]\].

4-Nitrobenzyl carbamate prodrugs (**29a, 30a**) of DNA major groove alkylating pyrrolo\[2,1-c\]benzodiazepines (**29b**) \[[@B140]\], and of DNA minor groove alkylating tallimustine mustards (**30b**) \[[@B141]\] showed differential cytotoxicity towards cells in culture when cotreated with NTR plus cofactor NADH, but studies have not been reported in NTR-transfected cell lines. The enediyne prodrug (**31a**) showed moderately selective cytotoxicity (135 fold) in the NTR-transfected WiDr human colon carcinoma cell line \[[@B142]\]. Nitroheterocyclic carbamate trigger units have also been reported. The 2-nitroimidazole carbamate prodrug (**32a**) of an amino-duocarmycin effector (**32b**) was 20-fold more toxic to NTR-transfected SKOV-3 human ovarian carcinoma cell line over the wild-type \[[@B143]\], extending the types of trigger units that can be used for this purpose.

Quinones
--------

Quinones can be excellent substrates for NTR (the k~cat~ for menadione is 4.2×10^4^ min^−1^ compared with 360 min^−1^ for CB1954) \[[@B117]\], but this is not universal; mitomycin C is a poor substrate \[[@B129]\]. The quinones EO9 (**33a**) and AZQ (**34a**) ([Figure 10](#F10){ref-type="fig"}) generate DNA-reactive species when reduced, but were less than three-fold more cytotoxic in NTR-transfected V79 cells compared to wild-type cells \[[@B144]\].

PRODRUGS FOR HORSE-RADISH PEROXIDASE (HRP)
==========================================

Introduction
------------

HRP is an iron-containing heme peroxidase that is well known to oxidize a variety of phenols and amines, including indole-3-acetic acid, without requiring added hydrogen peroxide as a cofactor. The mechanism of oxidation by HRP has been widely studied, and shown to involve a series of free radical intermediates of varying iron oxidation levels \[[@B145]\].

Indole-3-acetic acid (IAA; 35a)
-------------------------------

Indole-3-acetic acid, a catabolite of tryptophan and a plant growth hormone, is relatively nontoxic to mammalian cells. It is oxidized by HRP, initially to a nitrogen-centred radical-cation species that rapidly fragments via a carbon-centred benzyl radical. However, both of these radical species are extremely short-lived, and unlikely to account for the observed bystander effects of IAA. The 3-methylene-2-oxindole (**35b**) ([Figure 10](#F10){ref-type="fig"}), derived from the hydroperoxide of the benzyl radical by an unclear pathway, has been suggested as the active diffusing species, able to react with DNA \[[@B145]\]. This is sufficiently long-lived to generate a bystander effect, and sufficiently lipophilic (log P + 1.35) to diffuse rapidly by passive diffusion \[[@B146]\]. HRP transfection effectively sensitized human T24 bladder carcinoma cells to IAA under both normoxic and anoxic conditions. IAA also elicted a significant, selective enhancement of radiation-mediated cytotoxicity in T24 cells transiently transfected with the HRP, showing sensitizer enhancement ratios (SER) ranging from 2.6 to 5.4 \[[@B147]\].

5-Fluoroindole-3-acetic acid (FIAA; 36a)
----------------------------------------

This prodrug is related to IAA, and despite being less rapidly oxidized by HRP to the corresponding effector (**36b**) (rate constant 3.8 × 10^2^ mol^−1^sec^−1^ compared to 3.8×10^3^ mol^−1^sec^−1^ for IAA) is more cytotoxic than IAA in a range of HRP-transfected human and rodent tumor cell lines \[[@B148]\]. Plasma levels of 1 mmol and tumor levels of 200 μmol of FIAA were seen in mice bearing murine carcinoma NT tumors, after IP administration of 50 mg/kg FIAA.

PRODRUGS FOR GUANINE RIBOSYLTRANSFERASE (XGRPT)
===============================================

Introduction
------------

The *E. coli gpt* gene encodes a xanthine-guanine phosphoribosyl transferase (XGRPT) that has various xanthine and guanine analogues as substrates \[[@B149]\].

6-Thioxanthine (6-TX; 37a)
--------------------------

6-Thioxanthine (**37a**) is a relatively nontoxic compound (it is a catabolite of the clinically used antimetabolite 6-thioguanine), and is a substrate for *E. coli* XGRPT, being converted to the toxic ribophosphate (**37b**) ([Figure 11](#F11){ref-type="fig"}). Rat C6 glioma cells retrovirally transduced with *E. coli* XGRPT were more than 20-fold sensitized to 6-TX (IC~50~ of 2.5 μmol compared to \> 50 μmol) \[[@B149]\]. It showed only a weak bystander effect in mixed cocultures \[[@B150]\], which is not unexpected in view of the very hydrophilic (log D~7~ − 5.52), charged nature of the phosphorylated active species **37b**. The prodrug was moderately active in intracerebral C6 glioma xenografts in nude mice, with an 80% reduction in intracerebral tumor volume and a 28% increase in mean survival, following intratumoral injection of 6-TX \[[@B150]\].

PRODRUGS FOR GLYCOSIDASE ENZYMES
================================

Introduction
------------

Glycosidase enzymes have been used mostly in ADEPT, because their very hydrophilic sugar-bearing substrates show slow cell uptake. However, as with the case of the CPG2 enzyme, studies with secreted forms of β-glucuronidase and β-galactosidase show that these enzymes can also be used for GDEPT, in conjunction with anthracycline-based prodrugs. Both human and *E. coli* enzymes have been used.

HM1826 (38a)
------------

OVCAR-3 cells transfected (using a cationic lipid transfecting agent) with plasmids encoding *E. coli*- or human β-glucuronidase were equally sensitized to both the glucuronide prodrug DOX-GA3 and the effector doxorubicin produced from it ([Figure 12](#F12){ref-type="fig"}), suggesting good uptake and conversion of the prodrug, but the bacterial enzyme was more efficient. Studies with mixed cell cultures showed a strong bystander effect \[[@B151]\]. However, most work has been done using secreted \[[@B152]\] or surface-tethered \[[@B153]\] forms of the enzymes, with prodrugs such as HMR1826 (**38a**). Despite the high DNA binding of the released doxorubicin effector **19b**, moderate to good bystander effects were reported in culture and in vivo.

Anthracycline acetals
---------------------

As noted in "Anthracycline acetals", anthracycline carbinolamines such as **22b** are extremely potent cytotoxins, probably because of their spontaneous conversion to iminium ions that can alkylate DNA. The glucuronide and galactosyl prodrugs (**39a** and **40a**, respectively) are substrates for *E. coli* β-glucuronidase and β-galactosidase, from which that release the carbinolamine **22b** (see [Figure 7](#F7){ref-type="fig"}). In cell culture they were about 10^4^- and 10^6^-fold more toxic respectively to human A375 melanoma cells in the presence of the enzymes \[[@B154], [@B155]\] (see also "Anthracycline acetals"). While this is only a simple assay (the activating enzymes would need to be surface-tethered in a GDEPT application because of the very hydrophilic prodrugs), the very large differential cytotoxicity is noteworthy.

PRODRUGS FOR THYMIDINE PHOSPHORYLASE (TP)
=========================================

Introduction
------------

The endogenous enzyme thymidine phosphorylase (TP), which is reported to occur to a greater extent in tumor cells than in normal tissue, is a monomeric 55-kd enzyme that dephosphorylates thymidine and related pyrimidine antimetabolites such as 5′-deoxy-5-fluorouridine \[[@B156]\].

5′-Deoxy-5-fluorouridine (5′-DFUR; 41a)
---------------------------------------

LS174T human colon carcinoma cells transfected with the human TP gene were up to 40-fold sensitized to 5′-DFUR, which is converted to 5-FU (**10b**) by TP ([Figure 13](#F13){ref-type="fig"}). The degree of sensitization correlated with the extent of expression of TP, and in the cocultures a bystander effect was seen that did not require cell-cell contact \[[@B156]\]. Transfection of PC-9 human lung adenocarcinoma cells with platelet-derived endothelial cell growth factor (identical to human TP) resulted in a 50-fold increase in levels of enzyme expression, and sensitized them to both 5′-DFUR and tegafur \[[@B157]\]. MCF-7 breast cancer cells transfected with the TP had up to 165-fold increased sensitivity to 5′-DFUR (but not to 5-FU) in culture, and substantial bystander effects \[[@B158]\].

PRODRUGS FOR METHIONINE-α, γ-LYASE (MET)
========================================

Introduction
------------

Many tumors are methionine-dependent, and show elevated levels of methionine synthesis \[[@B159]\]. Thus the enzyme methionine-α, γ-lyase, which degrades the amino acid methionine to ketobutyrate, ammonia, and methylthiol, has been of therapeutic interest, and xenografts expressing the MET gene from *Pseudomonas putida* grow more slowly than wild-type tumors \[[@B160]\].

Selenomethionine (SeMET; 42a)
-----------------------------

Selenomethionine (SeMET) is a relatively toxic and very polar (log D~7~ − 3.15) analogue of the natural amino acid methionine, and is a substrate for MET which converts it to ketobutyrate, ammonia, and the moe lipophilic methylselenol (**42b**) ([Figure 14](#F14){ref-type="fig"}). Cells transduced by the adenovirus-delivered MET gene from *Pseudomonas putida* showed up to a 1000-fold increase in sensitivity to SeMET, and showed a strong bystander effect \[[@B160]\]. The enzyme converts SeMET to methylselenol, which damages mitochondria by oxidative stress (production of superoxide and other reactive oxgyen species), resulting in the release of cytochrome c and activation of the caspase cascade and apoptosis. SeMET inhibited the growth of MET-transfected rat hepatoma N1S1 ascites in nude mice, showing substantial delays in body weight gain due to growth of the tumor ascites \[[@B160]\].

CONCLUSIONS
===========

There are many issues to be considered in the choice of prodrugs for a particular activating enzyme. While the most obvious are the high turnover by the enzyme and the large differential cytotoxicity between the prodrug and the activated form, another important early consideration was to select compounds (eg, GCV, 5-FU, CPA, IRT) that were already in clinical use. This avoided the regulatory difficulties associated with the combination of a new therapeutic agent and a new activating technology.

Also of importance is the nature of the cytoxicity of the activated drug. Most of the early prodrugs released antimetabolites that act only on cycling cells. However, clinical solid tumors are slow-growing and contain hypoxic regions, resulting in considerable proportions of noncycling tumor cells. This requires prolonged dosing with cell cycle-specific agents to ensure high tumor cell killing. Thus there has been increasing interest ("Prodrugs for CYP enzymes," "Prodrugs for Carboxypeptidases (CP)", and "Prodrugs for Nitroreductase (NTR)" sections) in prodrugs that release DNA cross-linking agents, a class of cytotoxins that are less cell cycle-specific. The potential advantage of these compounds is shown by the fact that single dose protocols can provide curative effects in tumor xenograft models \[[@B4]\].

Later studies have also drawn attention to the importance of the maximizing bystander effects, and this review has focused on the importance of the lipophilicity, charge, and macromolecular binding of both prodrugs and their effectors ([Table 1](#T1){ref-type="table"}). Suicide gene therapy is a promising but very complex technology, and to be broadly clinically useful will require maximization of the therapeutic properties of all of the components. We are slowly learning how to do this for the prodrugs.
